157 related articles for article (PubMed ID: 15814651)
1. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
2. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
3. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
Danson S; Ranson M; Denneny O; Cummings J; Ward TH
Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
[TBL] [Abstract][Full Text] [Related]
4. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
Dehn DL; Inayat-Hussain SH; Ross D
J Pharmacol Exp Ther; 2005 May; 313(2):771-9. PubMed ID: 15665137
[TBL] [Abstract][Full Text] [Related]
5. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
6. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
7. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
8. Role of NADPH cytochrome P450 reductase in activation of RH1.
Begleiter A; Leith MK; Patel D; Hasinoff BB
Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
[TBL] [Abstract][Full Text] [Related]
9. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
11. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
12. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
13. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
Nemeikaite-Ceniene A; Dringeliene A; Sarlauskas J; Cenas N
Acta Biochim Pol; 2005; 52(4):937-41. PubMed ID: 15940348
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.
Hussein D; Holt SV; Brookes KE; Klymenko T; Adamski JK; Hogg A; Estlin EJ; Ward T; Dive C; Makin GW
Br J Cancer; 2009 Jul; 101(1):55-63. PubMed ID: 19491903
[TBL] [Abstract][Full Text] [Related]
16. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Kakadiya R; Dong H; Lee PC; Kapuriya N; Zhang X; Chou TC; Lee TC; Kapuriya K; Shah A; Su TL
Bioorg Med Chem; 2009 Aug; 17(15):5614-26. PubMed ID: 19576785
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
Park MT; Song MJ; Oh ET; Lee H; Choi BH; Jeong SY; Choi EK; Park HJ
Br J Pharmacol; 2011 Jun; 163(3):567-85. PubMed ID: 21250978
[TBL] [Abstract][Full Text] [Related]
20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
